Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
Moebius Medical
Moebius Medical Overview
Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis. The company's lead product, MM-II, is a patent-protected intra-articular biolubricant injection for the treatment of mild to moderate symptomatic knee osteoarthritis.
MM-II consists of proprietary liposomes whose structure facilitates cartilage surface gliding, thus reducing pain and preventing further wear and friction that can lead to joint damage. MM-II has demonstrated its ability to reduce osteoarthritic pain in a double-blind, randomized controlled trial conducted at Hadassah Medical Center, Israel.
In 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal to further develop MM-II. Moebius Medical conducts the requisite preclinical studies and assumes responsibility for product development and manufacturing through the end of phase 2 studies. Sun Pharma assumes responsibility for clinical studies, regulatory submissions, and product commercialization.
In December 2020, the FDA cleared the company's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II.